Crisis of Confidence: Novartis Faces Investor Backlash Following String of Clinical Setbacks
Novartis, the Swiss pharmaceutical titan, is currently grappling with more than just the $30 billion evaporation of its market capitalization...
novartis
Novartis Targets Oncology Leadership with $1.5B Acquisition of ADC Innovator Myricx Bio
In a significant move to reshape the future of precision oncology, pharmaceutical giant Novartis has announced a definitive agreement to...
